British Journal of Clinical Pharmacology

Article	Citations
Issue Highlights	261
Evaluation of the Prescribing Skills Assessment implementation, performance and medical student experience in Australia and New Zealand	92
Opioid‐related deaths and their counterpart by occurrence era, age group and coimplicated drugs: Scotland vs. England and Wales	65
The impact of including a medication review in an integrated care pathway: A pilot study	62
Physiologically based pharmacokinetic modelling to predict potential drug–drug interactions of dersimelagon (MT‐7117)	57
Population pharmacokinetics of long‐term hydroxychloroquine therapy in patients with rheumatic diseases	55
Polygenic modelling and machine learning approaches in pharmacogenomics: Importance in downstream analysis of genome‐wide association study data	48
Selected Abstracts from Pharmacology 2024	48
Concentration‐QTc analysis of soticlestat in healthy adults: An alternative to a thorough QT study	47
Evaluation of adherence monitoring in buprenorphine treatment: A pilot study using timed drug assays to determine accuracy of testing	46
Exploring the contribution of genetic variants to high sunitinib exposure in patients with cancer	46
The association between proton pump inhibitor use and systemic anti‐tumour therapy on survival outcomes in patients with advanced non‐small cell lung cancer: A systematic review and meta‐analysis	44
Analysis of factors influencing the relationship between voriconazole plasma concentrations and adverse effects in a paediatric population	44
A comprehensive assessment of statin discontinuation among patients who concurrently initiate statins and CYP3A4‐inhibitor drugs; a multistate transition model	44
Acute cardiovascular effects associated with the use of prescription medications: A Danish nationwide screening study	44
Investigating started sample size, completed sample size and drop‐out rate in 10 252 phase III clinical trials: Insights from ClinicalTrials.gov	43
Health technology assessment of paediatric medicines: European landscape, challenges and opportunities inside the conect4children project	41
Evaluation of critical parameters in the hollow‐fibre system for tuberculosis: A case study of moxifloxacin	39
Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort	39
A population pharmacokinetic model based on HPTN 077 of long‐acting injectable cabotegravir for HIV PrEP	39
Drug–drug interaction study with itraconazole supplemented with physiologically based pharmacokinetic modelling to characterize the effect of CYP3A inhibitors on venglustat pharmacokinetics	38
Changes in suspected adverse drug reaction reporting via the yellow card scheme in Wales following the introduction of a National Reporting Indicator	37
Drug reaction with eosinophilia and systemic symptoms induced by paclitaxel, a rare combination	36
Adverse events of alpelisib: A postmarketing study of the World Health Organization pharmacovigilance database	35
Cardiovascular events of Bruton's tyrosine kinase inhibitors: A real‐world study based on the United States Food and Drug Administration Adverse Event Reporting System database	34

Effects of itraconazole and carbamazepine on the pharmacokinetics of nirmatrelvir/ritonavir in healthy adults	32
	32
	31
Associations between potentially inappropriate prescribing and increased number of medications with postdischarge health outcomes among geriatric rehabilitation inpatients: RESORT study	31
A 10‐year retrospective study of antibacterial‐induced thrombocytopenia in a women and children hospital using China Hospital Pharmacovigilance System and Visual Basic for Applications	31
Cardiovascular concentration–effect relationships of amodiaquine and its metabolite desethylamodiaquine: Clinical and preclinical studies	31
Statistical inference in abstracts of 3 influential clinical pharmacology journals analysed using a text‐mining algorithm	31
	30
Comment on “The effectiveness and safety of topical beta‐receptor blocker in treating superficial infantile haemangiomas: A meta‐analysis including 20 studies”	29
Influence of N‐acetyltransferase 2 gene polymorphisms on the in vitro metabolism of the epidermal growth factor receptor inhibitor rociletinib	29
Physostigmine should be used more readily for antimuscarinic toxicity: PRO	29
Aortic intramural haematoma associated with the use of nintedanib	29
Pharmacokinetics and tolerability of the maturation inhibitor GSK3640254 coadministered with darunavir/ritonavir and/or etravirine in healthy adults	28
Antidepressants are not safe during pregnancy and in women of child‐bearing age	28
Issue Information	28
Postoperative ileus after digestive surgery: Network meta‐analysis of pharmacological intervention	28
Colchicine enhances β adrenoceptor‐mediated vasodilation in men with essential hypertension	27
Statin treatment effectiveness and the SLCO1B1*5 reduced function genotype: Long‐term outcomes in women and men	27
Making pharmaceutical companies report what matters about innovation	27
BC Clinical impact of medication reviews with follow‐up in cardiovascular older patients in primary care: A cluster‐randomized controlled trial	26
Gabapentin utilization among older adults with different cognitive statuses enrolled in the National Alzheimer's Coordinating Center (2006–2019)	26
Population pharmacokinetic/pharmacodynamic modelling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosis	26
Human hypoxia models in aerospace medicine: Potential applications for human pharmacological research	25
Infringement of clinical pharmacist's authority	25
A new model to predict the risk of major gastrointestinal bleeding in patients on direct oral anticoagulants (dabigatran and rivaroxaban)	24
A narrative review of vaccine pharmacovigilance during mass vaccination campaigns: Focus on myocarditis and pericarditis after COVID‐19 mRNA vaccination	24
Does the intact nephron hypothesis provide a reasonable model for metformin dosing in chronic kidney disease?	24
Issue Information	24
Issue Information	23
Serum uric acid lowering mediated by glucagon‐like peptide‐1 receptor agonists: Emerging considerations	23
Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium–glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults	23
	22
Establishment of a children's Drugs and Therapeutics Committee to ensure evidence‐based and cost‐effective medical treatment for children	22
Model‐based dosing optimization and therapeutic drug monitoring practices of teicoplanin in patients with complicated or non‐complicated methicillin‐resistant staphylococcus aureus infection	22
External validation of a pharmacokinetic model for target‐controlled infusion of cefazolin as a prophylactic antibiotic	22
Development of a predictive model for nephrotoxicity during tacrolimus treatment using machine learning methods	21
Rhabdomyolysis during concomitant ticagrelor and rosuvastatin: A breast cancer resistance protein‐mediated drug interaction?	21
Combatting climate change using education and training in pharmacology and therapeutics	21
Angiotensin‐converting enzyme inhibitors attenuate circulating CAF22 and physical decline in congestive heart failure: Diagnostic implications of CAF22	20
Effects of intraoperative low‐dose esketamine on postoperative pain after vestibular schwannoma resection: A prospective randomized, double‐blind, placebo‐controlled study	20
Correction	20
Acceptance of stakeholder comments during EMA scientific guideline public consultations: Legitimacy of the quadruple helix model of innovation	20
Pharmacodynamic modelling and exposure–response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders	20
Impact of monitoring approaches on data quality in clinical trials	19
	19
Issue highlights	19
	19
Moving forward to ‘put people first’	18
	18
Gaps and opportunities in sustainable medicines use in resource limited settings: A situational analysis of Uganda	18

Issue Information	18
Impact of the publication of the Finnish Meds75+ database on the use of potentially inappropriate medications in older persons	18
Tranexamic acid‐associated fatal status epilepticus in a paediatric non‐cardiac surgery: A case report and literature review	18
Optimal dosing of enoxaparin in overweight and obese children	18
Safety of off‐label dose reduction of non‐vitamin K antagonist oral anticoagulants in patients with atrial fibrillation	18
Evaluating prediction methods for glomerular filtration to optimise drug doses in obese and nonobese patients	18
Linezolid and the risk of QT interval prolongation: A pharmacovigilance study of the Food and Drug Administration Adverse Event Reporting System	18
Intravenous Lipid Emulsion does NOT have a role in severe poisoning: CON	17
Acalabrutinib CYP3A‐mediated drug–drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy	17
Erythema nodosum induced by Covid‐19 Pfizer‐BioNTech mRNA vaccine: A case report and brief literature review	17
Incidence of elevated creatine phosphokinase between daptomycin alone and concomitant daptomycin and statins: A systematic review and meta‐analysis	17
Impact of piperacillin unbound fraction variability on dosing recommendations in critically ill patients	17
Tocilizumab for reduction of mortality in severe COVID‐19 patients: How should we GRADE it?	17
Bioavailability and cardiovascular effects of adrenaline administered by Anapen 500 μg auto‐injector in healthy volunteers	17
Drug reaction with eosinophilia and systemic symptoms (DRESS): A tertiary care centre retrospective study	17
Transcranial magnetic stimulation as biomarker of excitability in drug development: A randomized, double‐blind, placebo‐controlled, cross‐over study	17
Dopamine agonists for the treatment of pituitary tumours: From ergot extracts to next generation therapies	17
	17
Physicians' and pharmacists' views and experiences regarding use of direct oral anticoagulants in clinical practice	17
Paracetamol toxicity in mild overdose in combination with opioids: A retrospective observational study	16
Issue Highlights 89‐1	16
Systemic exposure to hydroxychloroquine and its relationship with outcome in severely ill COVID‐19 patients in New York City	16
Design of a pharmacokinetic/pharmacodynamic model for administration of low dose peripheral norepinephrine during general anaesthesia	16
Potential drug–drug interactions when managing status epilepticus patients in intensive care: A cohort study	16
Effect of the human endotoxin challenge on tedizolid tissue penetration	16
Epidural methadone and morphine pharmacokinetics and clinical effects in healthy volunteers: A randomized, crossover‐design trial	16
Incidence, clinical classification and risk factors of cyclosporin A‐induced liver injury in allogeneic haematopoietic stem cell transplant recipients	16
Inflammation‐mediated drug interactions of olokizumab and cytochrome P450 activities in patients with rheumatoid arthritis	16
Clinical characteristics and prognosis of liver injury induced by immune checkpoint inhibitors in patients with malignancies: A real‐world retrospective study	16
Fully independent validation and updating of a clinical pharmacy prioritizing risk score in an infectious disease hospital ward	16
Clinical pharmacology considerations and drug–drug interactions with long‐acting cabotegravir and rilpivirine relevant to sub‐Saharan Africa	15
Influence of baseline QTc on sotalol‐induced prolongation of ventricular repolarization in men and women	15
Pharmacokinetics of oral ciprofloxacin in adult patients: A scoping review	15
The role of placebo response in the efficacy outcome assessment in viloxazine extended‐release pivotal trials in paediatric subjects with attention‐deficit/hyperactivity disorder	15
Evaluation of safety and pharmacokinetics of bismuth‐containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication	15
Determinants for under‐ and overdosing of direct oral anticoagulants and physicians' implementation of clinical pharmacists' recommendations	15
Methaemoglobinaemia and the radical curative efficacy of 8‐aminoquinoline antimalarials	15
Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP‐5862, in patients with B‐cell malignancies and in healthy subjects using a populatio	15
Cardiac toxicity associated with pharmacokinetic drug–drug interaction between crizotinib and sofosbuvir/velpatasvir: A case report	15
Apixaban or enoxaparin: Which is better for thromboprophylaxis after total hip and total knee arthroplasty in Indian patients?	15
Therapeutic drug monitoring of osimertinib in EGFR mutant non‐small cell lung cancer by dried blood spot and plasma collection: A pilot study	14
The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenone	14
Effect of a strong CYP3A4 inhibitor and inducer on the pharmacokinetics of senaparib (IMP4297) in healthy volunteers: A drug–drug interaction study	14
Does coprescribing nonsteroidal anti‐inflammatory drugs and oral anticoagulants increase the risk of major bleeding, stroke and systemic embolism?	14
Maternal and neonatal outcomes after benzodiazepine and benzodiazepine agonist exposure during pregnancy in women with mental disorders	14
Issue Information	14
Anticholinergic deprescribing: A case report demonstrating improved cognition and function with minimal adverse withdrawal effects	14
Glycochenodeoxycholate and glycodeoxycholate 3‐O‐glucuronides, but not hexadecanedioate and tetradecanedioate, detected weak inhibition of OATP1B caused by GDC‐0810 in humans	14
Comparison of a polypharmacy‐based scale with Charlson comorbidity index to predict 6‐month mortality in chronic complex patients after an ED visit	14
Epithelial lining fluid concentrations of ceftriaxone in children with community‐acquired pneumonia	14
Modelling the progression of illicit substance use patterns from real‐world evidence	14
Adherence and persistence with direct oral anticoagulants by dose regimen: A systematic review	14
Revisiting systematic reviews on deprescribing trials to better inform future practice and research	14
Prospective evaluation of pregnancy outcomes after gestational exposure to prazosin	14
Triple antithrombotic therapy and dual therapy – What is the evidence base?	14
Impact of pharmacist intervention in reducing vancomycin‐associated acute kidney injury: A systematic review and meta‐analysis	14
Patterns of suboptimal antipsychotic use and misuse in Australia: What can routinely collected data tell us?	14
Older adults' adherence to medications and willingness to deprescribe: A substudy of a randomized clinical trial	14
Differences in the location of bleeding with direct oral anticoagulants vs. vitamin K antagonists: A study in the World Health Organization's pharmacovigilance database	14
Physiologically‐based pharmacokinetic modelling guided dose evaluations of nirmatrelvir/ritonavir in renal impairment for the management of COVID‐19	13
Adverse reactions with levamisole vary according to its indications and misuse: A systematic pharmacovigilance study	13
The use of C‐reactive protein testing and antibiotic prescribing in Italy: A population‐based study in primary care	13
Higher incidence of neurotoxicity and skin hyperpigmentation in renal transplant patients treated with polymyxin B	13
Letter to the editor concerning the article: ‘The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: An overview’	13
Are patients living far from hospital at higher risk of late adjuvant chemotherapy for colon cancer?	13
Patient‐reported, observer‐reported and performance outcomes in qualification procedures at the European Medicines Agency 2013–2018	13
Evaluation of adherence to antipsychotics: A real‐world data study using four different dosing assumptions	13
Adverse fetal and neonatal outcomes following in‐utero exposure to oxcarbazepine: A systematic review and meta‐analysis	13
Superiority of ceftazidime off‐label high‐dose regimen in PK/PD target attainment during treatment of extensively drug‐resistant Pseudomonas aeruginosa infections in cancer patients	13
Correction to “EMA commentary on the guideline on quality, nonclinical and clinical aspects of medicinal products containing genetically modified cells”	13
Issue Information	13
	13
Physiologically based pharmacokinetic modelling of treprostinil after intravenous injection and extended‐release oral tablet administration in healthy volunteers: An extrapolation to other patient pop	13
ChatGPT in pharmacometrics? Potential opportunities and limitations	13
Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System	13
Nebulised sargramostim in pulmonary alveolar proteinosis	13
Innovations in pharmacovigilance studies of medicines in older people	12
A randomized phase I study of the safety and pharmacokinetics of BI 1291583 in healthy Japanese male subjects	12
Effect of renal function on the risk of thrombocytopaenia in patients receiving linezolid therapy: A systematic review and meta‐analysis	12
Pharmacological profile of ALKS 7119, an investigational compound evaluated for the treatment of neuropsychiatric disorders, in healthy volunteers	12

Issue Information	12
Population pharmacokinetics and exposure–response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY	12
Comprehensive population pharmacokinetic modelling of sugemalimab, an anti‐programmed death‐ligand 1 (PD‐L1) human monoclonal antibody, in patients with solid tumours or lymphomas across multiple Phas	12
Betalactam hypersensitivity: The importance of delabelling in primary care	12
Improving prescribing outcomes in undergraduate medical training	12
Impact of codeine rescheduling on prescribing of codeine and other opioids: Interrupted time series analyses using Australian general practice data	12
Management of combined oral antithrombotic therapy by an antithrombotic stewardship program: A prospective study	12
Cardiovascular complications of modern multiple myeloma therapy: A pharmacovigilance study	12
An artificial intelligence algorithm for co‐clustering to help in pharmacovigilance before and during the COVID‐19 pandemic	12
Clinical research for saliva‐based therapeutic drug monitoring of linezolid	12
Methotrexate toxicity and glucarpidase: A call for dose optimization	12
Impact of treosulfan exposure on clinical outcome after allogeneic stem cell transplantation in children: A substudy of 2 phase 2 trials	12
Effect of oral clonidine on pain reduction in patients with opioid use disorder in the emergency department: A randomized clinical trial	12
Efficiency of computerized clinical decision support systems involving anticoagulants: A flashmob study in Dutch hospital pharmacies	12
AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval	12
Stability for 6 months and accuracy of a specific enteral caffeine base preparation for a multisite clinical trial	12
Issue Highlights	12
Sensitivity of estimated tacrolimus population pharmacokinetic profile to assumed dose timing and absorption in real‐world data and simulated data	12
Issue Information	12
Utilization and expenditure on medicines for the management of osteoporosis in Ireland: A repeated cross‐sectional study	12
The impact of treatment choices on potential drug–drug interactions in hypertensive patients	12
Pharmacokinetics, safety and efficacy study in pregnancy and existing cumulative data/evidence to support clinical use and labelling of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in pre	11
Author Index	11
A case of acute pulmonary complication due to botulinum toxin: Patient with central pontine myelinolysis developed acute respiratory distress syndrome after botulinum neurotoxin type A injection into	11
Pristinamycin‐induced toxic epidermal necrolysis: A case report	11
Drug‐induced Sweet's syndrome: A case/non‐case study in the French pharmacovigilance database	11
Association of income and educational levels on initiation of oral anticoagulant therapy in patients with incident atrial fibrillation: A Finnish nationwide cohort study	11
Proton pump inhibitors are associated with incident type 2 diabetes mellitus in a prospective population‐based cohort study	11
Public preferences for pharmacogenetic testing in the NHS: Embedding a discrete choice experiment within service design to better meet user needs	11
Estimation of adherence to medication treatment in presence of censoring	11
Key factors associated with 6‐thioguanine and 6‐methylmercaptopurine nucleotide concentrations in children treated by thiopurine for acute leukaemia and inflammatory bowel disease	11
Cellular pharmacology of NRTI anabolites in PBMCS and platelets among persons with HIV receiving ABC/3TC‐ or TAF/FTC‐based art	11
Effects of dalteparin on anti‐Xa activities cannot be predicted in critically ill COVID‐19 patients	11
Quantification of sertraline maternal/fetal ratio and amniotic fluid concentration using a pregnancy physiologically based pharmacokinetic model	11
Pharmacogenomic testing in paediatrics: Clinical implementation strategies	11
Using Japanese big data to investigate novel factors and their high‐risk combinations that affect vancomycin‐induced nephrotoxicity	11
Intranasal vitamin B12 administration in elderly patients: A randomized controlled comparison of two dosage regimens	11
Fluvoxamine for COVID‐19 ICU patients?	11
The pharmacokinetic differences between 10‐ and 15‐μg daily vitamin D doses	11
Can nebulised HepArin Reduce morTality and time to Extubation in patients with COVID‐19 Requiring invasive ventilation Meta‐Trial (CHARTER‐MT): Protocol and statistical analysis plan for an investigat	11
Population pharmacokinetics of ABC/DTG/3TC FDC to support dosing in PEDS with HIV‐1 (IMPAACT 2019)	11
Case report: Dolutegravir dosing post‐Roux‐en‐Y gastric bypass surgery	11
Letter to the editor concerning the article: “Artificial intelligence in clinical pharmacology: A case study and scoping review of large language models and bioweapon potential”	11
Pregabalin poisoning: Evaluation of dose‐toxicity relationship	11
Evaluation of published population pharmacokinetic models to inform tacrolimus dosing in adult heart transplant recipients	11
Quo vadis (where are you going) pharmacovigilance?	11
Association between reversal agents (sugammadex vs. neostigmine) for neuromuscular block and postoperative pulmonary complications: A retrospective analysis	11
Therapeutic drug monitoring of thiopurines: Effect of reduced 6‐thioguanine nucleotide target levels in inflammatory bowel disease patients	11
Large paracetamol overdose – Higher dose NAC is NOT required	11
Medicines legislation and regulation in the United Kingdom 1500‐2020	10
Post‐injury benzodiazepine and opioid use among older adults involved in road traffic crashes: A Swedish register‐based longitudinal study	10
Use of population pharmacokinetic‐pharmacodynamic modelling to inform antimalarial dose optimization in infants	10
Angiotensin II receptor blockers (ARBs) and manufacturing contamination: A retrospective National Register Study into suspected associated adverse drug reactions	10
Past, present and future of drug safety: Editorial	10
Pharmacokinetic study of erlotinib in a pregnant woman with advanced non‐small cell lung cancer and observation of the effects on the child growth	10
Cancer drug applications to the EMA and the FDA: A comparison of new drugs and extension of indication in terms of approval decisions and time in review	10
A machine learning model for predicting blood concentration of quetiapine in patients with schizophrenia and depression based on real‐world data	10
Development of a USP‐4 IVIVC methodology for LAI antivirals: Case studies with cabotegravir and rilpivirine	10
The importance of CYP2C19 genotype in tacrolimus dose optimization when concomitant with voriconazole in heart transplant recipients	10
Tapentadol and oxycodone reduce cingulate glutamate in healthy volunteers	10
A systematic review of methods used to conduct decentralised clinical trials	10
Malaria in pregnancy: Modern approaches—Spotlight commmentary	10
Post‐marketing safety concerns with nirmatrelvir: A disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System	10
Iatrogenic copper deficiency: Risks and cautions with zinc prescribing	10
Deprescribing interventions for gabapentinoids in adults: A scoping review	10
How to assess pharmacogenomic tests for implementation in the NHS in England	10
A placebo‐controlled investigation of the analgesic effects, abuse liability, safety and tolerability of a range of oral cannabidiol doses in healthy humans	10
Evaluation of the effect of ritlecitinib on the pharmacokinetics of caffeine in healthy participants	10
Chemometrics as a valuable tool for evaluating interactions between antiretroviral drugs and food	10
An assessment of the effects of neurokinin1receptor antagonism against nausea and vomiting: Relative efficacy, sites of action and lessons for future drug development	10
Lemborexant levels in breast milk after single doses in healthy, lactating women	10
Population pharmacokinetic modelling of fibrinogen in patients with congenital or acquired—chronic or acute—hypofibrinogenaemia	10
A first‐in‐human study of the anti‐inflammatory profibrinolytic TMS‐007, an SMTP family triprenyl phenol	9
A meta‐analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis and dermatitis	9
Exposure–response modelling of osimertinib in patients with non‐small cell lung cancer	9
Pharmacokinetic characterization of favipiravir in patients with COVID‐19	9
A systematic review and meta‐analysis of dabigatran peak and trough concentration in adults	9
Reported congenital malformations after exposure to non‐tumour necrosis factor inhibitor biologics: A retrospective comparative study in EudraVigilance	9
Co‐prescription of low‐dose methotrexate and trimethoprim‐sulfamethoxazole and the 30‐day risk of death among older adults: A cohort study	9
Development and validation of a self‐report measure of practical barriers to medication adherence: The medication practical barriers to adherence questionnaire (MPRAQ)	9
Evaluation of the inhibitory effects of itraconazole on letermovir	9
Spotlight commentary: Safety and sustainability of eye drops—More than meets the eye	9
Systematic review and meta‐analysis of vancomycin therapeutic level for treatment of vancomycin‐sensitive enterococcal infections	9
Developing a physiologically based pharmacokinetic model of apixaban to predict scenarios of drug–drug interactions, renal impairment and paediatric populations	9
Absorption, metabolism and excretion of opicapone in human healthy volunteers	9
The CredibleMeds® list: Usage of QT interval prolonging drugs in Germany and discordances with prescribing information	9
Determination of the optimal obesity‐adjusted dosing weight for enoxaparin	9
N‐of‐1 trials to facilitate evidence‐based deprescribing: Rationale and case study	9
Menstrual abnormalities after COVID‐19 vaccination in the Netherlands: A description of spontaneous and longitudinal patient‐reported data	9
Impact of age, sex and cytochrome P450 genotype on quetiapine and N‐desalkylquetiapine serum concentrations: A study based on real‐world data from 8118 patients	9
Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target	9
The association of potentially inappropriate medications, polypharmacy and anticholinergic burden with readmission and emergency room revisit after discharge: A hospital‐based retrospective cohort stu	9
Prescription opioid use in Australian women of reproductive age: Implications for unplanned pregnancies	9
Drug–drug interactions with warfarin: A systematic review and meta‐analysis	9
Regulatory authority and clinical acceptability: Physicians' responses to regulatory drug safety warnings	9